ProQR Therapeutics N.V. (PRQR) Earnings Call Transcripts
ProQR Therapeutics N.V.'s Latest Earnings Call - April 8, 2026
In the first quarter of 2026, ProQR Therapeutics (PRQR:US) reported significant advancements in its clinical pipeline, particularly with its lead program AX-0810 for cholestatic diseases. The company is on track to report target engagement data from healthy volunteers later this quarter, which is crucial for its development strategy. ProQR maintained its guidance, indicating it is funded into mid-2027, while emphasizing the potential of its new programs, including AX-0811 for NTCP and AX-0422 for Hurler syndrome. Revenue and earnings figures were not disclosed in the call, but management's focus on pipeline progress suggests a positive outlook for future performance.
Reported metrics
| Metric | Value |
|---|---|
| Funding Guidance | $mid-2027 (inline) |
| Clinical Data Readouts | Multiple expected in 2026 (positive) |
| AX-0811 CTA Filing | Mid-2026 (positive) |
| AX-0422 CTA Filing | Early 2027 (positive) |
| Initial Clinical Data for AX-0811 | End of 2026 (positive) |
| AX-0810 Target Engagement Data | Q2 2026 (positive) |
Guidance from management
ProQR maintained its funding guidance into mid-2027 while emphasizing the importance of upcoming clinical data readouts across its pipeline. The company is focused on advancing AX-0810 and its new programs, with specific timelines for CTA filings and initial data releases.
What management said
Yes, that's a great question. So the patient cohorts will indeed be conducted in PSC patients because this is an adult population. So while biliary atresia is the key indication, we plan to pursue AX-0810 for both PSC and biliary atresia. The PSC cohorts will allow us to understand the translation from healthy volunteers to the disease context. And we think that will be very valuable information to help us bridge tow...
Yes. So obviously, this is to be discussed with the regulators. But the plan is that we indeed pursue an accelerated development path where we look at liver biomarkers and liver health, liver stiffness, and those will help us towards an accelerated approval with then long-term follow-up as opposed market commitment. We expect to treat different stages of the disease post Kasai procedure. But it's still to be designed...
What analysts pressed on
Analysts expressed concerns about the prioritization of biliary atresia over PSC and the implications for future development. There were also questions regarding the potential efficacy of AX-0810 in PSC patients based on upcoming data readouts, as well as the overall strategy for managing multiple indications.
Main topics on the call
- Lead Program Progress - AX-0810 — Management confirmed that AX-0810 is on track to report target engagement data from healthy volunteers later this quarter, with a focus on biliary atresia as the initial indication for Phase II development. CEO Daniel de...
- AI-Enabled Discovery Platform — ProQR highlighted advancements in its AI-driven discovery engine, which has significantly reduced the time from discovery to candidate selection. Gerard Platenburg noted, "What used to take us up to 3 years using manual ...
- New Pipeline Programs — The introduction of AX-0422 for Hurler syndrome was announced, with CTA-enabling activities expected to be completed by early 2027. This program addresses a significant unmet need, as noted by Cristina Lopez Lopez, who s...
- Clinical Strategy for AX-0811 — AX-0811, a next-generation Axiomer editing oligonucleotide, is expected to file a CTA in mid-2026, with initial clinical data anticipated by year-end. Management emphasized that this program reflects continued innovation...
Read the full ProQR Therapeutics N.V. transcript (April 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 21 calls on record spanning June 22, 2020 to September 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 21 ProQR Therapeutics N.V. earnings call transcripts on record, spanning June 22, 2020 to September 30, 2026. Based on this history, ProQR Therapeutics N.V. reports semi-annually. The most recent call on file is dated September 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PRQR
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 21
- First call
- June 22, 2020
- Most recent
- September 30, 2026
- Reporting cadence
- semi-annually